Biohaven Ltd. (BHVN)

NYSE: BHVN · Real-Time Price · USD
54.05
+1.30 (2.45%)
Oct 8, 2024, 2:30 PM EDT - Market open
2.45%
Market Cap 5.45B
Revenue (ttm) n/a
Net Income (ttm) -746.61M
Shares Out 100.95M
EPS (ttm) -9.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,089,022
Open 52.24
Previous Close 52.75
Day's Range 52.18 - 55.58
52-Week Range 24.60 - 62.21
Beta 4.11
Analysts Strong Buy
Price Target 61.92 (+14.71%)
Earnings Date Nov 12, 2024

About BHVN

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 239
Stock Exchange NYSE
Ticker Symbol BHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for BHVN stock is "Strong Buy." The 12-month stock price forecast is $61.92, which is an increase of 14.71% from the latest price.

Price Target
$61.92
(14.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEW HAVEN, Conn. , Oct. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

5 days ago - PRNewsWire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

NEW HAVEN, Conn. , Oct. 1, 2024 /PRNewswire/ -- Biohaven Ltd.

7 days ago - PRNewsWire

Biohaven Announces Proposed Public Offering of Common Shares

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Biohaven Ltd.

7 days ago - PRNewsWire

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven initiated a pivotal Phase 2 trial evaluating BHV-2100 in the acute treatment of migraine BHV-2100 is a potential first-in-class, potent, orally administered Transient Receptor Potential Melas...

8 days ago - PRNewsWire

Overlooked Stock: BHVN

Biohaven (BHVN) shares surged after the company's troriluzole drug showed significant slowed progression of spinocerebellar ataxia, a rare neurological disease. George Tsilis shares how the promising ...

14 days ago - Schwab Network

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression...

14 days ago - Seeking Alpha

Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug

Biohaven (BHVN) shares soared 15% Monday after the biotech firm announced positive results from a study of its experimental treatment for a rare neurological condition.

14 days ago - Investopedia

Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise

Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of tre...

15 days ago - Benzinga

Biohaven's stock surges as treatment slows progress of neurological disorder

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.

15 days ago - Market Watch

Biohaven's genetic disease drug meets main trial goal

Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the brain, the company said on Monday.

15 days ago - Reuters

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia ...

15 days ago - PRNewsWire

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn. , Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd.

17 days ago - PRNewsWire

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $440 million on June 30, 2024 Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform advancing...

2 months ago - PRNewsWire

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment...

2 months ago - Seeking Alpha

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platform BHV-1300 demon...

4 months ago - PRNewsWire

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the pote...

Other symbols: REGN
4 months ago - PRNewsWire

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, ...

5 months ago - Seeking Alpha

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven'...

5 months ago - PRNewsWire

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

NEW HAVEN, Conn. , April 18, 2024 /PRNewswire/ -- Biohaven Ltd.

6 months ago - PRNewsWire

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechanism...

6 months ago - PRNewsWire

How Biohaven's experimental obesity drug could prevent muscle loss

Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.

7 months ago - CNBC Television

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, ep...

7 months ago - PRNewsWire

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, s...

7 months ago - Seeking Alpha

Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncol

Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzh...

9 months ago - PRNewsWire

Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

10 months ago - PRNewsWire